Pfizer’s (PFE) portfolio includes a large variety of drugs, vaccines, and consumer healthcare products. Pfizer’s business is classified into two business segments: Innovative Health and Essential Health.
PFE’s Innovative Health segment
Pfizer’s Innovative Health segment was previously the Innovative Pharmaceuticals business. This segment contributed ~59% of PFE’s total revenues in 2Q17, and analysts expect the segment to contribute ~60% of total revenues in 3Q17.
The segment reported revenues of ~$7.7 billion in 2Q17, which was 9% higher at constant exchange rates, compared with its revenues of ~$7.1 billion in 2Q16. This growth was driven by increased sales of Chantix-Champix, Eliquis, Ibrance, Lyrica, and Xeljanz.
PFE’s Essential Health segment
Pfizer’s Essential Health segment was previously the Established Pharmaceuticals business and includes legacy established products as well as the legacy Hospira products acquired by Pfizer in 2015.
This segment reported revenues of ~$5.2 billion in 2Q17, which was nearly 12% lower than its revenues of ~$6.0 billion in 2Q16. This fall was due to lower sales of legacy established products, Peri-LOE products, sterile injectable products, and PFE’s divestment of Hospira infusion systems. But the decline was partially offset by strong sales of biosimilars.
Alliance revenues totaled $715 million in 2Q17—90% higher than its $376 million in 2Q16.